Media

Onxeo receives EPO Intent-to-Grant Notice for key AsiDNA™ patent

Onxeo receives EPO Intent-to-Grant Notice for key AsiDNA™ patent, extending IP protection in Europe until 2031 Composition of matter patent to be granted in Europe on several products including AsiDNA™ as such until 2031, with potential extension to 2036 Onxeo’s intellectual property for DNA-targeting technologies, products and combinations now protected by 10 patent families worldwide   Paris (France), January 25,…read more →

Onxeo Provides Update on Litigation with SpeBio/SpePharm

Paris (France), January 23, 2018 – 09:30 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), (“Onxeo” or the “Company”), a biotechnology company specializing in the development of innovative drugs in oncology, and notably rare and resistant forms of cancer, announces that it has submitted its conclusions to the Paris Court of Appeal concerning merits of the litigation…read more →

Financial Agenda 2018

Onxeo Announces its Financial Agenda for 2018 Paris (France), January 23, 2018 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” or the “Company”), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announced its financial agenda for 2018. Event Date* Full-year 2017…read more →

Onxeo to attend Key Investor and Partnering Conferences in H1 2018

Paris (France), January 3, 2018 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” or the “Company”), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announced that its management team will attend the following key investor and partnering conferences in the first…read more →

Onxeo Establishes Scientific Advisory Board with International Experts in DNA-targeting

Professor Tomas Lindahl, DNA Repair Pioneer and 2015 Nobel Prize laureate, will serve as Chair of the Scientific Advisory Board Paris (France), November 28, 2017 – 6:00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” or the “Company”), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or…read more →

Onxeo Provides Strategy Update and Reports 2017 Third Quarter Financial Information

Company completes strategic shift to innovative DNA-targeting programs and platON™ chemistry platform of decoy oligonucleotides Development of lead product AsiDNA™ in line with plans Paris (France), October 26, 2017 – 08:00 pm CEST– Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – ISIN FR0010095596), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology,…read more →

Onxeo Reports First Instance Decision from the Commercial Court of Paris in the Lawsuit against SpeBio/SpePharm

Paris (France), October 17, 2017 – 10 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” or the “Company”), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announced the Commercial Court of Paris’ decision in the litigation which started in 2009 between Onxeo on…read more →

Onxeo Introduces platON™, a Proprietary Chemistry Platform of Decoy Oligonucleotides

PlatON™ will generate new best-in-class DNA-targeting drug candidates starting in 2018 In parallel, the Company advances its robust development programs for AsiDNA™ and belinostat, supported by recent promising combination data and preliminary clinical data expected in 2018 Company is well-financed into early 2020, with the resources to support the current clinical development plan Paris (France), October 2, 2017 – 07:00…read more →

Onxeo announces compelling preclinical data in combination for its two innovative compounds, AsiDNA™ and belinostat

Results demonstrate a very strong synergistic effect between AsiDNA™,  first-in-class DNA break repair inhibitor (DBRi), and histone deacetylase inhibitors (HDACi) This synergy is particularly high for the combination of  its two proprietary assets, AsiDNA™ and belinostat, Potential application of AsiDNA™ in combination with any HDACi fully covered by a key worldwide patent application   Paris (France), September 28, 2017 –…read more →